Metabolic & Cardiometabolic
SGLT1 inhibition decreases postprandial glucose
📅 Last reviewed: 2026-08-11 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Human trials (RCT / n-of-1)
How the studies fall
What the evidence shows
Blocking intestinal SGLT1 delays and blunts glucose absorption, lowering the postprandial rise. Human evidence is consistent and includes a tracer study showing the effect is genuinely absorptive, not renal. The independence caveat is the important one: sotagliflozin IS LX4211 renamed, so the three strongest human trials are one sponsor's drug programme, tagged as a single group.
The evidence (5)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Martinussen C, et al. 2020 · American journal of physiology. Endocrinology and metabolism | RCT | supports | moderate | Randomized controlled crossover, n=10 post-RYGB. Canagliflozin delayed glucose absorption (time-to-peak 3-OMG 50 vs 132 min, p<0.01) and reduced insulin and glucose excursions. |
| Zambrowicz B, et al. 2013 · Clinical therapeutics | RCT | supports | moderate | Randomized 3-way crossover, n=18 T2DM. LX4211 (alone and with sitagliptin) significantly improved blood glucose with less insulin vs sitagliptin monotherapy, attributed to reduced SGLT1-mediated intestinal glucose absorption. |
| Powell DR, et al. 2020 · The Journal of clinical endocrinology and metabolism | RCT | supports | high | Sotagliflozin and canagliflozin decreased AUC for rate-of-appearance of oral glucose, postprandial glucose and insulin vs placebo (p<0.05); sotagliflozin lowered PPG AUC0-5h vs both placebo and canagliflozin. Dual-tracer, double-blind 3-period crossover, n=24 healthy. Effect attributed to prolonged local intestinal SGLT1 inhibition persisting >=5h. |
| Io F, et al. 2019 · European journal of pharmacology | animal | supports | moderate | SGL5213, a gut-restricted SGLT1 inhibitor, improved postprandial hyperglycaemia in STZ-diabetic rats at >=1 mg/kg and increased residual glucose in distal gut, confirming the absorptive mechanism. Rat. |
| Zambrowicz B, et al. 2013 · Clinical therapeutics | RCT | supports | moderate | Randomized double-blind placebo-controlled dose-timing study, n=12 healthy. LX4211 reduced postprandial glucose; effect depended on dose timing relative to meals, consistent with local intestinal SGLT1 blockade. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.